- Home
- BLTE
BLTE
Belite Bio Inc
as 11-18-2025 3:25pm EST
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 4.1B | IPO Year: | 2022 |
| Target Price: | $105.00 | AVG Volume (30 days): | 96.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $49.00 - $125.01 | Next Earning Date: | 11-10-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Belite Bio Inc News
BLTE Breaking Stock News: Dive into BLTE Ticker-Specific Updates for Smart Investing
MT Newswires
2 months ago
Belite Bio to Raise $275 Million in Private Placement
GlobeNewswire
2 months ago
Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors
MT Newswires
6 months ago
Sector Update: Health Care Stocks Flat to Lower Pre-Bell Wednesday
MT Newswires
6 months ago
Belite Bio Says FDA Grants Breakthrough Therapy Tag to Stargardt Disease Drug
GlobeNewswire
6 months ago
Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease
GlobeNewswire
6 months ago
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
Simply Wall St.
6 months ago
We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn
GuruFocus.com
6 months ago
Belite Bio Inc (BLTE) Q1 2025 Earnings Call Highlights: Strong Financial Position Amid Rising ...
Compare BLTE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BLTE Belite Bio Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.